The Experts below are selected from a list of 831 Experts worldwide ranked by ideXlab platform

Miles A. Kirchin - One of the best experts on this subject based on the ideXlab platform.

  • safety and adverse effects during 24 hours after contrast enhanced mri with Gadobenate Dimeglumine multihance in children
    Pediatric Radiology, 2013
    Co-Authors: G Schneider, Miles A. Kirchin, Hellmut Schurholz, Arno Bucker, Peter Fries
    Abstract:

    Gadolinium-based MR contrast agents have long been considered safe for routine diagnostic imaging. However, the advent of nephrogenic systemic fibrosis (NSF) among certain patients with severe renal insufficiency has brought the issue of safety into question. Nowhere is safety of greater concern than among children who frequently require multiple contrast-enhanced MRI examinations over an extended period of time. To retrospectively evaluate the safety of Gadobenate Dimeglumine for contrast-enhanced (CE) MRI across a range of indications. Two hundred pediatric inpatients (age: 4 days to 15 years) underwent CE MRI as part of clinical routine. The children received a Gadobenate Dimeglumine dose of either 0.05 mmol/kg body weight (liver, abdominal imaging, musculoskeletal imaging, brain and other rare indications) or 0.1 mmol/kg bodyweight (cardiovascular imaging, MR-urography). Young (< 8 years) children with congenital heart disease were intubated and underwent MRA evaluation with controlled ventilation. Monitoring for adverse events was performed for at least 24 h after each Gadobenate Dimeglumine injection. Depending on clinical necessity, laboratory measurements and, in some cases, vital sign and ECG determinations were made before and after contrast injection. Safety was evaluated by age group, indication and dose administered. No clinically adverse events were reported among children who had one MRI scan only or among children who had several examinations. There were no changes in creatinine or bilirubin levels even in very young children. No adverse events were recorded during the first 24 h following administration of Gadobenate Dimeglumine in 200 children.

  • solid hypervascular liver lesions accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after Gadobenate Dimeglumine administration
    Investigative Radiology, 2011
    Co-Authors: Giovanni Morana, Miles A. Kirchin, Luigi Grazioli, Maria Pia Bondioni, Niccolo Faccioli, Alessandro Guarise, Günther Schneider
    Abstract:

    Purpose:To evaluate hepatobiliary phase magnetic resonance imaging with Gadobenate Dimeglumine for differentiation of benign hypervascular liver lesions from malignant or high-risk lesions.Methods and Materials:Retrospective assessment was performed of 550 patients with 910 hypervascular lesions (30

  • contrast enhanced mra of the renal and aorto iliac femoral arteries comparison of Gadobenate Dimeglumine and gadofosveset trisodium
    European Journal of Radiology, 2011
    Co-Authors: Roberto Iezzi, Gilles Soulez, Siegfried Thurnher, Günther Schneider, Miles A. Kirchin, Ningyan Shen, Gianpaolo Pirovano, Alberto Spinazzi
    Abstract:

    Abstract Rationale and objectives Dedicated contrast agents are now available for contrast-enhanced magnetic resonance angiography (CE-MRA). This study retrospectively compares the safety and diagnostic performance data from Phase III regulatory trials performed to evaluate Gadobenate Dimeglumine (MultiHance®) and gadofosveset trisodium (Vasovist®) for renal and peripheral CE-MRA. Materials and methods Similar examination and blinded assessment methodology was utilized in all studies to determine the safety and diagnostic performance of the agents for detection of significant (>50%) steno-occlusive disease. Digital Subtraction Angiography (DSA) was used as the standard of truth. Diagnostic performance data (sensitivity, specificity, predictive values [PVs], and likelihood ratios [LRs]) were compared (Chi-square test). Results CE-MRA with Gadobenate Dimeglumine was more specific (92.4% vs. 80.5%, p  Conclusion The diagnostic performance of CE-MRA for the detection of significant steno-occlusive disease is similar with gadofosveset and Gadobenate Dimeglumine although the rate of adverse events appears higher with gadofosveset.

  • first pass and high resolution steady state magnetic resonance angiography of the peripheral arteries with Gadobenate Dimeglumine an assessment of feasibility and diagnostic performance
    Investigative Radiology, 2011
    Co-Authors: Michele Anzidei, Miles A. Kirchin, Carlo Catalano, Alessandro Napoli, Fulvio Zaccagna, Beatrice Cavallo Marincola, Chiara Zini, R Passariello
    Abstract:

    Purpose To assess the feasibility of combined first-pass (FP) and steady-state (SS) contrast-enhanced magnetic resonance angiography (MRA) of the peripheral arteries with Gadobenate Dimeglumine (MultiHance) and to evaluate diagnostic performance relative to digital subtraction angiography (DSA). Materials and methods A total of 35 patients with symptomatic peripheral arterial occlusive disease (PAOD) underwent FP MRA (repetition time [TR]/echo time [TE]/flip angle [FA]/acquisition time [TA] = 3.5/1.2/30°/14s) at 1.5T after intravenous injection of 10 mL of Gadobenate Dimeglumine. Thereafter, SS imaging of the calf (TR/TE/FA/TA = 7.5/2.3/20°/40-130s) and femoropopliteal (TR/TE/FA/TA = 7.5/2.3/18°/130-240s) regions was performed after a second injection of 5 mL of Gadobenate Dimeglumine. All patients underwent conventional DSA. Three readers reviewed separate FP and FP+SS MRA datasets for image quality and presence/absence of clinically relevant PAOD. A fourth independent observer evaluated DSA images. The diagnostic performance (sensitivity, specificity, positive and negative predictive values) achieved with each dataset was determined and compared. Inter-reader agreement was assessed using kappa statistics. Results The image quality of 134 of 140 vascular regions was optimal or adequate on SS MRA. Inter-reader agreement was good to very good for assessments of FP (κ = 0.725) and combined FP+SS images (κ = 0.866). SS images improved diagnostic confidence in 34 (48.6%) femoropoliteal and 46 (65.7%) crural regions and altered final diagnosis in 8 (11.4%) and 10 (14.3%) regions, respectively. Global diagnostic accuracy increased from 92.9% on FP images to 95.9% on FP+SS images, with significant (P = 0.0384) improvement in the crural region. Conclusion SS MRA of the peripheral arteries is feasible with Gadobenate Dimeglumine and potentially improves diagnostic performance in patients with symptomatic PAOD.

  • Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of Gadobenate Dimeglumine and gadofosveset trisodium.
    European Journal of Radiology, 2011
    Co-Authors: Roberto Iezzi, Gilles Soulez, Siegfried Thurnher, Günther Schneider, Miles A. Kirchin, Ningyan Shen, Gianpaolo Pirovano, Alberto Spinazzi
    Abstract:

    Abstract Rationale and objectives Dedicated contrast agents are now available for contrast-enhanced magnetic resonance angiography (CE-MRA). This study retrospectively compares the safety and diagnostic performance data from Phase III regulatory trials performed to evaluate Gadobenate Dimeglumine (MultiHance ® ) and gadofosveset trisodium (Vasovist ® ) for renal and peripheral CE-MRA. Materials and methods Similar examination and blinded assessment methodology was utilized in all studies to determine the safety and diagnostic performance of the agents for detection of significant (>50%) steno-occlusive disease. Digital Subtraction Angiography (DSA) was used as the standard of truth. Diagnostic performance data (sensitivity, specificity, predictive values [PVs], and likelihood ratios [LRs]) were compared (Chi-square test). Results CE-MRA with Gadobenate Dimeglumine was more specific (92.4% vs. 80.5%, p p  = 0.022) than CE-MRA with gadofosveset in the detection of significant renal artery stenosis. The average sensitivity was higher for gadofosveset (74.4% vs. 67.3%, p  = 0.011) in peripheral vessels although Gadobenate Dimeglumine was more specific (93.0% vs. 88.2%, p p  = 0.66). PPVs were higher ( p Conclusion The diagnostic performance of CE-MRA for the detection of significant steno-occlusive disease is similar with gadofosveset and Gadobenate Dimeglumine although the rate of adverse events appears higher with gadofosveset.

Günther Schneider - One of the best experts on this subject based on the ideXlab platform.

  • solid hypervascular liver lesions accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after Gadobenate Dimeglumine administration
    Investigative Radiology, 2011
    Co-Authors: Giovanni Morana, Miles A. Kirchin, Luigi Grazioli, Maria Pia Bondioni, Niccolo Faccioli, Alessandro Guarise, Günther Schneider
    Abstract:

    Purpose:To evaluate hepatobiliary phase magnetic resonance imaging with Gadobenate Dimeglumine for differentiation of benign hypervascular liver lesions from malignant or high-risk lesions.Methods and Materials:Retrospective assessment was performed of 550 patients with 910 hypervascular lesions (30

  • contrast enhanced mra of the renal and aorto iliac femoral arteries comparison of Gadobenate Dimeglumine and gadofosveset trisodium
    European Journal of Radiology, 2011
    Co-Authors: Roberto Iezzi, Gilles Soulez, Siegfried Thurnher, Günther Schneider, Miles A. Kirchin, Ningyan Shen, Gianpaolo Pirovano, Alberto Spinazzi
    Abstract:

    Abstract Rationale and objectives Dedicated contrast agents are now available for contrast-enhanced magnetic resonance angiography (CE-MRA). This study retrospectively compares the safety and diagnostic performance data from Phase III regulatory trials performed to evaluate Gadobenate Dimeglumine (MultiHance®) and gadofosveset trisodium (Vasovist®) for renal and peripheral CE-MRA. Materials and methods Similar examination and blinded assessment methodology was utilized in all studies to determine the safety and diagnostic performance of the agents for detection of significant (>50%) steno-occlusive disease. Digital Subtraction Angiography (DSA) was used as the standard of truth. Diagnostic performance data (sensitivity, specificity, predictive values [PVs], and likelihood ratios [LRs]) were compared (Chi-square test). Results CE-MRA with Gadobenate Dimeglumine was more specific (92.4% vs. 80.5%, p  Conclusion The diagnostic performance of CE-MRA for the detection of significant steno-occlusive disease is similar with gadofosveset and Gadobenate Dimeglumine although the rate of adverse events appears higher with gadofosveset.

  • Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of Gadobenate Dimeglumine and gadofosveset trisodium.
    European Journal of Radiology, 2011
    Co-Authors: Roberto Iezzi, Gilles Soulez, Siegfried Thurnher, Günther Schneider, Miles A. Kirchin, Ningyan Shen, Gianpaolo Pirovano, Alberto Spinazzi
    Abstract:

    Abstract Rationale and objectives Dedicated contrast agents are now available for contrast-enhanced magnetic resonance angiography (CE-MRA). This study retrospectively compares the safety and diagnostic performance data from Phase III regulatory trials performed to evaluate Gadobenate Dimeglumine (MultiHance ® ) and gadofosveset trisodium (Vasovist ® ) for renal and peripheral CE-MRA. Materials and methods Similar examination and blinded assessment methodology was utilized in all studies to determine the safety and diagnostic performance of the agents for detection of significant (>50%) steno-occlusive disease. Digital Subtraction Angiography (DSA) was used as the standard of truth. Diagnostic performance data (sensitivity, specificity, predictive values [PVs], and likelihood ratios [LRs]) were compared (Chi-square test). Results CE-MRA with Gadobenate Dimeglumine was more specific (92.4% vs. 80.5%, p p  = 0.022) than CE-MRA with gadofosveset in the detection of significant renal artery stenosis. The average sensitivity was higher for gadofosveset (74.4% vs. 67.3%, p  = 0.011) in peripheral vessels although Gadobenate Dimeglumine was more specific (93.0% vs. 88.2%, p p  = 0.66). PPVs were higher ( p Conclusion The diagnostic performance of CE-MRA for the detection of significant steno-occlusive disease is similar with gadofosveset and Gadobenate Dimeglumine although the rate of adverse events appears higher with gadofosveset.

  • diagnostic performance of Gadobenate Dimeglumine enhanced mr angiography of the iliofemoral and calf arteries a large scale multicenter trial
    American Journal of Roentgenology, 2007
    Co-Authors: Siegfried Thurnher, Christoph U. Herborn, Günther Schneider, Claudio Ballarati, S Miller, Georg Bongartz, Stefan O Schoenberg, Maria Assunta Cova, Giovanni Morana, Khusrow Niazi
    Abstract:

    OBJECTIVE. The purpose of this study was to compare Gadobenate Dimeglumine–enhanced MR angiography and unenhanced time-of-flight MR angiography for the detection of significant peripheral arterial occlusive disease using digital subtraction angiography as our reference standard.SUBJECTS AND METHODS. Two hundred seventy-two patients underwent MR angiography and digital subtraction angiography of the iliofemoral arteries. MR angiography was performed before (2D time-of-flight acquisitions) and after (spoiled gradient-echo acquisitions) the administration of 0.1 mmol/kg of Gadobenate Dimeglumine at 1–2 mL/s. Contrast-enhanced MR angiography and digital subtraction angiography of the calf arteries were performed in 241 of 272 participants. Images were evaluated on-site and by four blinded reviewers (three for MR angiography, one for digital subtraction angiography). Comparative diagnostic performance for the detection of significant (≥ 51% vessel lumen narrowing) disease was evaluated using the McNemar test a...

  • Gadobenate Dimeglumine enhanced mr angiography diagnostic performance of four doses for detection and grading of carotid renal and aorto iliac stenoses compared to digital subtraction angiography
    Journal of Magnetic Resonance Imaging, 2007
    Co-Authors: Günther Schneider, Siegfried Thurnher, Claudio Ballarati, Luigi Grazioli, Lorenzo Bonomo, Thomas J Kroencke, Riccardo Manfredi, Matthias Taupitz, Biagio Merlino, Ningyan Shen
    Abstract:

    Purpose To determine the diagnostic performance of contrast-enhanced MR angiography (CE-MRA) with four doses of Gadobenate Dimeglumine for detection of significant steno-occlusive disease of the carotid, renal, and pelvic vasculature. Materials and Methods Eighty-four patients with suspected disease of the renal (n = 16), pelvic (n = 41), or carotid (n = 27) arteries underwent CE-MRA (3D-spoiled gradient-echo sequences) at 1.5T. CE-MRA was performed with Gadobenate Dimeglumine at 0.025, 0.05, 0.1, or 0.2 mmol/kg (23, 24, 19, and 18 patients, respectively) administered at 2 mL/sec. Accuracy, sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) for detection of significant disease (>50% stenosis or occlusion for renal/pelvic arteries; >70% stenosis or occlusion for carotid arteries) was determined by three fully blinded, independent radiologists using conventional digital subtraction angiography (DSA) as reference standard. All comparisons were tested statistically (ANOVA, chi-square, and Mantel–Haenszel tests as appropriate) and reader agreement (kappa) was assessed. Results Values for accuracy, sensitivity, specificity, PPV, and NPV on CE-MRA were consistently higher for 0.1 mmol/kg Gadobenate Dimeglumine (accuracy = 95.2–97.3%, sensitivity = 84.2% (all readers), specificity = 96.9–99.2%, PPV = 80.0–94.1%, NPV = 97.6–97.7%). The greater accuracy of the 0.1 mmol/kg dose was significant (P < 0.01, all readers) compared to all other dose groups. Agreement between the three readers was good for all dose groups (kappa ≥0.58), with the highest percent agreement (85.7%) noted for the 0.1 mmol/kg dose. Conclusion Significantly better diagnostic performance on CE-MRA of the renal, pelvic, and carotid arteries is achieved with a Gadobenate Dimeglumine dose of 0.1 mmol/kg bodyweight. J. Magn. Reson. Imaging 2007;26:1020–1032. © 2007 Wiley-Liss, Inc.

R Passariello - One of the best experts on this subject based on the ideXlab platform.

  • first pass and high resolution steady state magnetic resonance angiography of the peripheral arteries with Gadobenate Dimeglumine an assessment of feasibility and diagnostic performance
    Investigative Radiology, 2011
    Co-Authors: Michele Anzidei, Miles A. Kirchin, Carlo Catalano, Alessandro Napoli, Fulvio Zaccagna, Beatrice Cavallo Marincola, Chiara Zini, R Passariello
    Abstract:

    Purpose To assess the feasibility of combined first-pass (FP) and steady-state (SS) contrast-enhanced magnetic resonance angiography (MRA) of the peripheral arteries with Gadobenate Dimeglumine (MultiHance) and to evaluate diagnostic performance relative to digital subtraction angiography (DSA). Materials and methods A total of 35 patients with symptomatic peripheral arterial occlusive disease (PAOD) underwent FP MRA (repetition time [TR]/echo time [TE]/flip angle [FA]/acquisition time [TA] = 3.5/1.2/30°/14s) at 1.5T after intravenous injection of 10 mL of Gadobenate Dimeglumine. Thereafter, SS imaging of the calf (TR/TE/FA/TA = 7.5/2.3/20°/40-130s) and femoropopliteal (TR/TE/FA/TA = 7.5/2.3/18°/130-240s) regions was performed after a second injection of 5 mL of Gadobenate Dimeglumine. All patients underwent conventional DSA. Three readers reviewed separate FP and FP+SS MRA datasets for image quality and presence/absence of clinically relevant PAOD. A fourth independent observer evaluated DSA images. The diagnostic performance (sensitivity, specificity, positive and negative predictive values) achieved with each dataset was determined and compared. Inter-reader agreement was assessed using kappa statistics. Results The image quality of 134 of 140 vascular regions was optimal or adequate on SS MRA. Inter-reader agreement was good to very good for assessments of FP (κ = 0.725) and combined FP+SS images (κ = 0.866). SS images improved diagnostic confidence in 34 (48.6%) femoropoliteal and 46 (65.7%) crural regions and altered final diagnosis in 8 (11.4%) and 10 (14.3%) regions, respectively. Global diagnostic accuracy increased from 92.9% on FP images to 95.9% on FP+SS images, with significant (P = 0.0384) improvement in the crural region. Conclusion SS MRA of the peripheral arteries is feasible with Gadobenate Dimeglumine and potentially improves diagnostic performance in patients with symptomatic PAOD.

  • high resolution steady state magnetic resonance angiography of the carotid arteries are intravascular agents necessary feasibility and preliminary experience with Gadobenate Dimeglumine
    Investigative Radiology, 2009
    Co-Authors: Michele Anzidei, Miles A. Kirchin, Carlo Catalano, Alessandro Napoli, Fulvio Zaccagna, Beatrice Cavallo Marincola, Cristina Neira, Daniel Geiger, R Passariello
    Abstract:

    Purpose:To prospectively evaluate the potential of Gadobenate Dimeglumine for high-resolution steady-state (SS) contrast-enhanced magnetic resonance angiography (CE-MRA) of the carotid arteries as an adjunct to conventional first-pass (FP) MRA, with computed tomography angiography (CTA) and digital

  • hepatocellular carcinoma in patients with cirrhosis qualitative comparison of Gadobenate Dimeglumine enhanced mr imaging and multiphasic 64 section ct
    Radiology, 2009
    Co-Authors: Daniele Marin, Carlo Catalano, Michele Di Martino, Antonino Guerrisi, Gianmaria De Filippis, M Rossi, Stefano Ginanni Corradini, Raffaele Masciangelo, R Passariello
    Abstract:

    Purpose: To prospectively investigate whether combined interpretation of dynamic and hepatobiliary phase magnetic resonance (MR) images can improve the accuracy of Gadobenate Dimeglumine–enhanced MR imaging in the detection of hepatocellular carcinoma (HCC) compared with either dynamic MR or multiphasic multidetector computed tomographic (CT) images alone. Materials and Methods: Institutional review board approval and informed patient consent were obtained. Fifty-two patients (39 men, 13 women; mean age, 68 years; range, 38–81 years) suspected of having HCC underwent Gadobenate Dimeglumine–enhanced MR imaging and multiphasic 64-section multidetector CT. Images were qualitatively analyzed independently by three observers in three separate reading sessions. The alternating free-response receiver operating characteristic (AFROC) method was used to analyze the results. Differences in sensitivity and positive predictive values were calculated at a statistical significance of P < .05. Results: A total of 67 HCC...

  • contrast enhanced mr mammography improved lesion detection and differentiation with Gadobenate Dimeglumine
    American Journal of Roentgenology, 2008
    Co-Authors: Federica Pediconi, Miles A. Kirchin, Gianpaolo Pirovano, Carlo Catalano, Simona Padula, Antonella Roselli, Valeria Dominelli, Sabrina Cagioli, R Passariello
    Abstract:

    OBJECTIVE. The objective of our study was to intraindividually compare 0.1 mmol/kg doses of Gadobenate Dimeglumine and gadopentetate Dimeglumine for contrast-enhanced breast MRI.SUBJECTS AND METHODS. Forty-seven women (mean age ± SD, 50.8 ± 12.9 years) with breast lesions classified as BI-RADS category 3, 4, or 5 for suspicion of malignancy underwent two identical MR examinations at 1.5 T separated by 48–72 hours. T1-weighted gradient-echo images were acquired before contrast administration and at 2-minute intervals after the randomized injection of gadopentetate Dimeglumine or Gadobenate Dimeglumine at 2 mL/s. Two blinded readers evaluated randomized image sets for lesion detection and differentiation as benign or malignant compared with histology. The McNemar exact test and the generalized estimating equation (GEE) were used to compare lesion detection rates and diagnostic performance in terms of sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV).RES...

  • breast lesion detection and characterization at contrast enhanced mr mammography Gadobenate Dimeglumine versus gadopentetate Dimeglumine
    Radiology, 2005
    Co-Authors: Federica Pediconi, Miles A. Kirchin, Carlo Catalano, R Occhiato, Fiammetta Venditti, Francesco Fraioli, Alessandro Napoli, R Passariello
    Abstract:

    PURPOSE: To prospectively and intraindividually compare equivalent (0.1 mmol per kilogram of body weight) doses of Gadobenate Dimeglumine and gadopentetate Dimeglumine for accuracy of detection and characterization of breast lesions at contrast material–enhanced magnetic resonance (MR) mammography. MATERIALS AND METHODS: Ethics committee approval and informed consent were obtained. Twenty-six consecutive women (mean age, 47.8 years) suspected of having a breast tumor at mammography and sonography underwent two identical MR examinations at 1.5 T; examinations were separated by more than 48 hours but less than 72 hours. A T1-weighted three-dimensional gradient-echo sequence was used, and images were acquired before and at 0, 2, 4, 6, and 8 minutes after randomized injection of gadopentetate Dimeglumine or Gadobenate Dimeglumine at an identical flow rate of 2 mL/sec. Separate and combined assessment of unenhanced, contrast-enhanced, and subtracted images was performed blindly by two readers in consensus. Acc...

Angelo Vanzulli - One of the best experts on this subject based on the ideXlab platform.

  • hepatobiliary phase in cirrhotic patients with different model for end stage liver disease score comparison of the performance of gadoxetic acid to Gadobenate Dimeglumine
    European Radiology, 2019
    Co-Authors: Claudia Khouri Chalouhi, Federica Vernuccio, Giuseppe Brancatelli, Francesca Rini, Piergiorgio Duca, Bruno Tuscano, Angelo Vanzulli
    Abstract:

    The purpose of this study was to compare the performance of Gadobenate Dimeglumine–enhanced MRI and gadoxetic acid–enhanced MRI in the hepatobiliary phase (HBP) in cirrhotic patients with different degrees of liver dysfunction. In this retrospective cross-sectional study, we analyzed the unenhanced phase and the HBP of 131 Gadobenate Dimeglumine–enhanced MRI examinations (Gadobenate Dimeglumine group) and 127 gadoxetic acid–enhanced MRI examinations (gadoxetic acid group) performed in 249 cirrhotic patients (181 men and 68 women; mean age, 64.8 years) from August 2011 to April 2017. For each MRI, the contrast enhancement index of the liver parenchyma was calculated and correlated to the Model For End-Stage Liver Disease (MELD) score (multiple linear regression analysis). A qualitative analysis of the adequacy of the HBP, adjusted for the MELD score (logistic regression analysis), was performed. The contrast enhancement index was inversely related (r = − 0.013) with MELD score in both gadoxetic acid and Gadobenate Dimeglumine group. At the same MELD score, the contrast enhancement index in the gadoxetic acid group was increased by a factor of 0.23 compared to the Gadobenate Dimeglumine group (p < 0.001), and the mean odds ratio to have an adequate HBP with gadoxetic acid compared to Gadobenate Dimeglumine was 3.64 (p < 0.001). The adequacy of the HBP in the gadoxetic acid group compared to the Gadobenate Dimeglumine group increased with the increase of the MELD score (exp(b)interaction = 1.233; p = 0.011). In cirrhotic patients, the hepatobiliary phase obtained with gadoxetic acid–enhanced MRI is of better quality in comparison to Gadobenate Dimeglumine–enhanced MRI, mainly in patients with high MELD score. • In cirrhotic patients, the adequacy of the hepatobiliary phase with gadoxetic acid–enhanced MRI is better compared to Gadobenate Dimeglumine–enhanced MRI. • Gadoxetic acid–enhanced MRI should be preferred to Gadobenate Dimeglumine–enhanced MRI in cirrhotic patients with MELD score > 10, if the hepatobiliary phase is clinically indicated. • In patients with high MELD score (> 15), the administration of the hepatobiliary agent could be useless; even though, if it is clinically indicated, we recommend to use gadoxetic acid given the higher probability of obtaining clinically relevant information.

  • multicenter double blind randomized intraindividual crossover comparison of Gadobenate Dimeglumine and gadopentetate Dimeglumine for mr angiography of peripheral arteries
    Radiology, 2010
    Co-Authors: S C Gerretsen, Christoph U. Herborn, Josef Vymazal, Siegfried Thurnher, Angelo Vanzulli, S Miller, Thierry Le F Maire, Henrik J Michaely, Harald Kramer, Martin N J M Wasser
    Abstract:

    Image quality and diagnostic accuracy for the detection of clinically relevant peripheral arterial occlusive disease are significantly improved at contrast material–enhanced MR angiography with 0.1 mmol/kg of Gadobenate Dimeglumine compared with 0.1 mmol/kg of gadopentetate Dimeglumine.

  • renal artery stenosis evaluation diagnostic performance of Gadobenate Dimeglumine enhanced mr angiography comparison with dsa
    Radiology, 2008
    Co-Authors: Gilles Soulez, Mieczyslaw Pasowicz, Marek Konopka, Luigi Grazioli, Giovanni Morana, G Benea, Juan Pablo Niedmann, Philippe Douek, Fritz Schaefer, Angelo Vanzulli
    Abstract:

    Purpose: To prospectively determine diagnostic performance and safety of contrast material–enhanced (CE) magnetic resonance (MR) angiography with 0.1 mmol per kilogram of body weight Gadobenate Dimeglumine for depiction of significant steno-occlusive disease (≥51% stenosis) of renal arteries, with digital subtraction angiography (DSA) as reference standard. Materials and Methods: This multicenter study was approved by local institutional review boards; all patients provided written informed consent. Patient enrollment and examination at centers in the United States complied with HIPAA. Two hundred ninety-three patients (154 men, 139 women; mean age, 61.0 years) with severe hypertension (82.2%), progressive renal failure (11.3%), and suspected renal artery stenosis (6.5%) underwent CE MR angiography with three-dimensional spoiled gradient-echo sequences after administration of 0.1 mmol/kg Gadobenate Dimeglumine at 2 mL/sec. Anteroposterior and oblique DSA was performed in 268 (91.5%) patients. Three indepe...

  • contrast enhanced mr angiography of the renal arteries blinded multicenter crossover comparison of Gadobenate Dimeglumine and gadopentetate Dimeglumine
    Radiology, 2005
    Co-Authors: Mathias Prokop, Günther Schneider, Miles A. Kirchin, Gianpaolo Pirovano, Angelo Vanzulli, Philippe Douek, Stefan G Ruehm, Mathias Goyen, Massimo Dapra, Alberto Spinazzi
    Abstract:

    PURPOSE: To prospectively and intraindividually compare 0.1 mmol/kg Gadobenate Dimeglumine with 0.2 mmol/kg gadopentetate Dimeglumine for contrast material–enhanced magnetic resonance (MR) angiography of the renal arteries. MATERIALS AND METHODS: Institutional review board approval was granted by each of three participating centers. The study accorded with international standards for good clinical practice and Declaration of Helsinki and subsequent amendments. Patients gave written informed consent before enrollment. Patients (n = 34) underwent two MR angiographic examinations more than 48 hours but less than 12 days apart. Gadobenate Dimeglumine followed by gadopentetate Dimeglumine was administered in 18 patients; the order of administration was reversed in 16 patients. A 1.5-T MR imager was used with a phase-encoded three-dimensional spoiled breath-hold pulse sequence. Two blinded independent readers qualitatively assessed randomized subtracted maximum intensity projection images. A three-point scale f...

  • evaluation of the accuracy of Gadobenate Dimeglumine enhanced mr imaging in the detection and characterization of focal liver lesions
    American Journal of Roentgenology, 2000
    Co-Authors: Gianpaolo Pirovano, Luigi Grazioli, Angelo Vanzulli, Ernst J Rummeny, Luis Martibonmati, Riccardo Manfredi, Alina Greco, Nicolaus Holzknecht, Heike E Daldruplink, Bernd Hamm
    Abstract:

    OBJECTIVE. We evaluated the extent to which hepatic lesion characterization and detection is improved by using Gadobenate Dimeglumine for enhancement of MR images.MATERIALS AND METHODS. Eighty-six patients were imaged before Gadobenate Dimeglumine administration, immediately after the 2 mL/sec bolus administration of a 0.05 mmol/kg dose (dynamic imaging), and at 60-120 min after the IV infusion at 10 mL/min of a further 0.05 nmol/kg dose (delayed imaging). The accuracy for lesion characterization was assessed for a total of 107 lesions. Sensitivity for lesion detection was assessed for a total of 149 lesions detected on either intra-operative sonography, iodized oil CT, CT during arterial portography, or follow-up contrast-enhanced CT as the gold standard.RESULTS. The accuracy in differentiating benign from malignant liver lesions increased from 75% and 82% (the findings of two observers) on unenhanced images alone, to 89% and 80% on dynamic images alone (p < 0.001, p = 0.8), and to 90.7% when combining t...

Carlo Catalano - One of the best experts on this subject based on the ideXlab platform.

  • first pass and high resolution steady state magnetic resonance angiography of the peripheral arteries with Gadobenate Dimeglumine an assessment of feasibility and diagnostic performance
    Investigative Radiology, 2011
    Co-Authors: Michele Anzidei, Miles A. Kirchin, Carlo Catalano, Alessandro Napoli, Fulvio Zaccagna, Beatrice Cavallo Marincola, Chiara Zini, R Passariello
    Abstract:

    Purpose To assess the feasibility of combined first-pass (FP) and steady-state (SS) contrast-enhanced magnetic resonance angiography (MRA) of the peripheral arteries with Gadobenate Dimeglumine (MultiHance) and to evaluate diagnostic performance relative to digital subtraction angiography (DSA). Materials and methods A total of 35 patients with symptomatic peripheral arterial occlusive disease (PAOD) underwent FP MRA (repetition time [TR]/echo time [TE]/flip angle [FA]/acquisition time [TA] = 3.5/1.2/30°/14s) at 1.5T after intravenous injection of 10 mL of Gadobenate Dimeglumine. Thereafter, SS imaging of the calf (TR/TE/FA/TA = 7.5/2.3/20°/40-130s) and femoropopliteal (TR/TE/FA/TA = 7.5/2.3/18°/130-240s) regions was performed after a second injection of 5 mL of Gadobenate Dimeglumine. All patients underwent conventional DSA. Three readers reviewed separate FP and FP+SS MRA datasets for image quality and presence/absence of clinically relevant PAOD. A fourth independent observer evaluated DSA images. The diagnostic performance (sensitivity, specificity, positive and negative predictive values) achieved with each dataset was determined and compared. Inter-reader agreement was assessed using kappa statistics. Results The image quality of 134 of 140 vascular regions was optimal or adequate on SS MRA. Inter-reader agreement was good to very good for assessments of FP (κ = 0.725) and combined FP+SS images (κ = 0.866). SS images improved diagnostic confidence in 34 (48.6%) femoropoliteal and 46 (65.7%) crural regions and altered final diagnosis in 8 (11.4%) and 10 (14.3%) regions, respectively. Global diagnostic accuracy increased from 92.9% on FP images to 95.9% on FP+SS images, with significant (P = 0.0384) improvement in the crural region. Conclusion SS MRA of the peripheral arteries is feasible with Gadobenate Dimeglumine and potentially improves diagnostic performance in patients with symptomatic PAOD.

  • high resolution steady state magnetic resonance angiography of the carotid arteries are intravascular agents necessary feasibility and preliminary experience with Gadobenate Dimeglumine
    Investigative Radiology, 2009
    Co-Authors: Michele Anzidei, Miles A. Kirchin, Carlo Catalano, Alessandro Napoli, Fulvio Zaccagna, Beatrice Cavallo Marincola, Cristina Neira, Daniel Geiger, R Passariello
    Abstract:

    Purpose:To prospectively evaluate the potential of Gadobenate Dimeglumine for high-resolution steady-state (SS) contrast-enhanced magnetic resonance angiography (CE-MRA) of the carotid arteries as an adjunct to conventional first-pass (FP) MRA, with computed tomography angiography (CTA) and digital

  • hepatocellular carcinoma in patients with cirrhosis qualitative comparison of Gadobenate Dimeglumine enhanced mr imaging and multiphasic 64 section ct
    Radiology, 2009
    Co-Authors: Daniele Marin, Carlo Catalano, Michele Di Martino, Antonino Guerrisi, Gianmaria De Filippis, M Rossi, Stefano Ginanni Corradini, Raffaele Masciangelo, R Passariello
    Abstract:

    Purpose: To prospectively investigate whether combined interpretation of dynamic and hepatobiliary phase magnetic resonance (MR) images can improve the accuracy of Gadobenate Dimeglumine–enhanced MR imaging in the detection of hepatocellular carcinoma (HCC) compared with either dynamic MR or multiphasic multidetector computed tomographic (CT) images alone. Materials and Methods: Institutional review board approval and informed patient consent were obtained. Fifty-two patients (39 men, 13 women; mean age, 68 years; range, 38–81 years) suspected of having HCC underwent Gadobenate Dimeglumine–enhanced MR imaging and multiphasic 64-section multidetector CT. Images were qualitatively analyzed independently by three observers in three separate reading sessions. The alternating free-response receiver operating characteristic (AFROC) method was used to analyze the results. Differences in sensitivity and positive predictive values were calculated at a statistical significance of P < .05. Results: A total of 67 HCC...

  • contrast enhanced mr mammography improved lesion detection and differentiation with Gadobenate Dimeglumine
    American Journal of Roentgenology, 2008
    Co-Authors: Federica Pediconi, Miles A. Kirchin, Gianpaolo Pirovano, Carlo Catalano, Simona Padula, Antonella Roselli, Valeria Dominelli, Sabrina Cagioli, R Passariello
    Abstract:

    OBJECTIVE. The objective of our study was to intraindividually compare 0.1 mmol/kg doses of Gadobenate Dimeglumine and gadopentetate Dimeglumine for contrast-enhanced breast MRI.SUBJECTS AND METHODS. Forty-seven women (mean age ± SD, 50.8 ± 12.9 years) with breast lesions classified as BI-RADS category 3, 4, or 5 for suspicion of malignancy underwent two identical MR examinations at 1.5 T separated by 48–72 hours. T1-weighted gradient-echo images were acquired before contrast administration and at 2-minute intervals after the randomized injection of gadopentetate Dimeglumine or Gadobenate Dimeglumine at 2 mL/s. Two blinded readers evaluated randomized image sets for lesion detection and differentiation as benign or malignant compared with histology. The McNemar exact test and the generalized estimating equation (GEE) were used to compare lesion detection rates and diagnostic performance in terms of sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV).RES...

  • Focal nodular hyperplasia: Intraindividual comparison of dynamic Gadobenate Dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging
    'Wiley', 2007
    Co-Authors: Daniele Marin, Andrea Laghi, Tonsok Kim, Masatoshi Hori, Takamichi Murakami, Riccardo Iannaccone, Carlo Catalano, Roberto Passariello
    Abstract:

    Purpose: To intraindividually compare the enhancement pattern of focal nodular hyperplasia (FNH) after dynamic administration of two bolus-injectable liver-specific MR contrast agents, ferucarbotran and Gadobenate Dimeglumine. Materials and Methods: A total of 19 patients with 24 FNHs underwent Gadobenate Dimeglumine- and ferucarbotran-enhanced MRI during the hepatic arterial-dominant phase (HAP; 25 seconds), the portal-venous phase (PVP; 60 seconds), and the equilibrium phase (EP; 180 seconds). Hepatospecific phases were acquired on T1-weighted images 120 minutes after Gadobenate Dimeglumine administration, and on T2-weighted images 10 minutes after ferucarbotran administration. Lesion enhancement was independently analyzed by two observers. The kappa statistic was determined to evaluate the agreement between the enhancement patterns of the lesions. Results: On Gadobenate Dimeglumine- enhanced MR images during HAP, PVP, and EP, FNHs were: hyperintense (24/20/13); isointense (0/4/11); and hypointense (0/0/0). On ferucarbotran-enhanced MR images during HAP, PVP, and EP, FNHs were: hyperintense (2/0/0); isointense (16/9/14); and hypointense (6/15/10). Overall, poor agreement between both contrast agents was observed. During the hepatospecific phases, most (20/24; 83%) FNHs showed a typical enhancement pattern during the delayed hepatospecific phase. Conclusion: The dynamic enhancement pattern of FNHs is significantly different between Gadobenate: Dimeglumine- and ferucarbotran-enhanced MRI. With respect to hepatospecific phase, the majority of FNHs showed a typical behavior on both contrast agents